The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder associated with a significant degree of functional disability and poor quality of life. Pharmacotherapy may have a substantial impact on the course and outcome of OCD. METHOD: We review the evidence supporting available strategies for the pharmacological treatment of OCD. RESULTS: Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice and are associated with improved health-related quality of life. Discontinuation is associated with relapse and loss of quality of life, implying treatment should continue long-term. A substantial minority of patients who fail to respond to SSRI may benefit from dose elevation or adjunctive antipsychotics, though long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking. CONCLUSION: The pharmacological evidence-base for the treatment of OCD is becoming increasingly robust. Treatment with SSRIs and clomipramine remains uncontroversial and improvements are sustained over time. Newer compounds targeting serotonin receptor subtypes and other neurotransmitter systems are undergoing evaluation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they continue to be limited by low remission (12–16) and high relapse rates (17, 18)”
In the citing paper
“Clomipramine has a less favorable side-effect profile than SSRIs [23].”
From Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults (2023) · cites this paper as [23]
In the citing paper
“The main pharmacological treatment for OCD are antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs) (Fineberg et al., 2013).”
From The role of habit in compulsivity (2016) · cites this paper as Fineberg et al., 2013
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550 · cited 2×
“Epidemiological surveys using Diagnostic and Statistical Manual of Mental Disorders third edition, third revised edition and fourth edition (DSM-III, DSM-III-R and DSM-IV) criteria suggest lifetime prevalence to range between 1% and 3% of the worldwide population (Robins et al., 1984; Weissman et al., 1994; Wittchen a…”
BackgroundMethodChildren's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045 · cited 1×
“From weeks 1 to 6 and at the 10-week end point, there was significant improvement on the Children’s Yale–Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997).”
MethodSize and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“…and Statistical Manual of Mental Disorders third edition, third revised edition and fourth edition (DSM-III, DSM-III-R and DSM-IV) criteria suggest lifetime prevalence to range between 1% and 3% of the worldwide population (Robins et al., 1984; Weissman et al., 1994; Wittchen and Jacobi, 2005).”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028 · cited 4×
“Recent guidelines (Greist et al., 2003; Koran et al., 2007) recommend continuation of pharmacotherapy for a minimum of 1–2 years in treatment-responsive individuals and emphasise the importance of long-term treatment from the outset.”
BackgroundMethodInfluential(2008) · Cited by 889
The Cross National Epidemiology of obsessive-compulsive disorder
Weisman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Browne, M. A. O., Rubio-Stipec, M., WICKRAMARATNE, P. J., et al. (1994) · Max Planck Institute for Plasma Physics · Cited by 688
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review
Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., Berlin, H. A., Menzies, L., Bechara, A., Sahakian, B. J., Robbins, T. W., Bullmore, E. T., & Hollander, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.185 · Cited by 654 · cited 1×
“Other neurotransmitters such as dopamine, noradrenaline and glutamate (Fineberg et al., 2010) are also likely to be involved.”
BackgroundSelf-citationA 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
Research works printed but not linked: 19
- Eser D, 2010, Core Evidence, 4, 171
- Fernandez CE, 1967, Actas Luso-Españolas de Neurología, Psiquiatría y Ciencias Afines, 26, 119
- Feusner JD, 2009, Psychopharmacological Bulletin, 42, 81
- Foa EB, 1987, Psychopharmacology Bulletin, 23, 8
- Freeman CPC, 1994, Journal of Clinical Psychiatry, 55, 301
- 10.1001/archpsyc.1990.01810180077011 · DOI · Paper page
- Greist JH, 1990, Journal of Clinical Psychiatry, 51, 292
- Leonard HL, 1988, Psychopharmacology Bulletin, 24, 93
- 10.1097/00004850-200301000-00004 · doi:10.1097/00004850-200301000-00004
- Miguel EC, 2010, American College of Neuropsychopharmacology, 49th Annual Meeting
- Pigott TA, 1992, New Research Program and Abstracts of the 145th Annual Meeting of the American Psychiatric Association
- Ravizza L, 2001, Fifth International Obsessive Compulsive Disorder Conference
- Smeraldi E, 1992, New Trends in Experimental and Clinical Psychiatry, 8, 63
- Szegedi A, 1996, Journal of Clinical Psychiatry, 57, 257
- Ushijima S, 1997, Japanese Journal of Neuropsychopharmacology, 19, 603
- Wagner KD, 1999, 39th Annual Meeting of the New Clinical Drug Evaluation Unit
- Weissman MM, 1994, Journal of Clinical Psychiatry, 55, 5
- Wheadon D, 1993, 32nd Annual Meeting of the American College of Neuropsychopharmacology
- Yaryura-Tobias JA, 1976, Current Therapy Research, 20, 541
Cited by
The role of habit in compulsivity
Gillan, C. M., Robbins, T. W., Sahakian, B. J., van den Heuvel, O. A., & van Wingen, G. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.033 · Cited by 292
“The main pharmacological treatment for OCD are antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs) (Fineberg et al., 2013).”
BackgroundDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., Banca, P., Gillan, C. M., Voon, V., Chamberlain, S. R., Cinosi, E., Reid, J., Shahper, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx088 · Cited by 183
“Of considerable interest, subthreshold OCD is found to be extremely common and such cases share a similar age of onset and symptom trajectory as OCD, suggesting a natural continuum of compulsive behavior exists affecting as many as 20% of the general population (Fineberg et al., 2013b).”
InfluentialSelf-citationBandelow, B., Baldwin, D., Abelli, M., Altamura, C., Dell’Osso, B., Domschke, K., Fineberg, N. A., Grünblatt, E., Jarema, M., Maron, E., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1181783 · Cited by 164
“Interest in the dopaminergic system came from the treatment of OCD using antipsychotics as augmenting agents alongside SSRIs (Fineberg et al. 2013).”
BackgroundInfluentialSelf-citationVeale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
“drugs as a class for augmentation of SSRI treatment resistant OCD [5,6].”
Background
Metadata
- Authors
- Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I.
- Affiliations
- Queen Elizabeth II Hospital (GB)
- Surrey and Borders Partnership NHS Foundation Trust (GB)
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2012-11-02
- Volume
- 47
- Issue
- 2
- Pages
- 121-141
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2150547685
- Cited by
- 122
- References
- 189
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 5 · 2015: 18 · 2014: 15 · 2013: 12 · 2012: 2
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Association for Psychopharmacology
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, pharmacotherapy, selective serotonin reuptake inhibitors, clomipramine, relapse, long-term treatment, health-related quality of life, serotonin receptor subtypes
- MeSH terms
- Clomipramine, Humans, Obsessive-Compulsive Disorder, Recurrence, Antipsychotic Agents, Selective Serotonin Reuptake Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond. https://app.cochat.ai/papers/10.1177/0004867412461958
- The paper
- Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013). Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867412461958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.